RDNT RadNet, Inc.data gap · 65% coveragelimited data
Health Care · Health Care Services · close $68.80 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
RadNet, Inc. (RDNT) has a ThetaGrade House Rating of 51/100 (grade C), ranking #128 of 150 in Health Care. Its strongest pillars are valuation (77) and growth (72); its weakest is balance sheet (29). Data gap: 5 factors without usable data, so 65% of the method weight is covered. TTM revenue growth is 18.9% and operating margin 3.1%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, EPS growth YoY (TTM), 4Q gross-margin change, P/E (inverted). Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 65% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 72| Revenue growth YoY (TTM) (22.2%) | 18.9% | 71 |
| EPS growth YoY (TTM) (0.0%)data gap | — | — |
| Revenue acceleration (11.1%) | 2.9% | 74 |
Profitability
weight 18.5% (→20.0%) · 33| Operating margin (20.0%) | 3.1% | 33 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 29| Net debt / EBITDA (10.7%) | 2.72× | 32 |
| Current ratio (5.3%) | 1.48 | 27 |
| Interest coverage (4.0%) | 1.01× | 24 |
Cash flow
weight 12.33% (→13.3%) · 34| FCF margin (6.7%) | 4.2% | 29 |
| FCF yield (6.7%) | 1.6% | 38 |
Valuation
weight 12.33% (→13.3%) · 77| P/E (inverted) (0.0%)data gap | — | — |
| EV/Sales (inverted) (13.3%) | 2.65× | 77 |
Technicals (EOD)
| RSI(14) | 43.3 |
| EMA 9 / 21 | 70.01 / 70.85 |
| 200-day SMA | 65.34 |
| Volume vs 20d avg | 0.63× |
| 20-day return | -11.5% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseDebt · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close.
Get rating changes like RDNT's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is RDNT's House Rating?
- RDNT scores 51 out of 100 (grade C) as of 2026-10-16, ranking #128 of 150 Health Care stocks we cover.
- What do analysts say about RDNT?
- We do not have enough analyst-sentiment data to score this stock.
- When does RDNT report earnings next?
- We do not have a reliable estimate for RDNT's next earnings date (irregular SEC filing history); a rough window is 2026-10-19 to 2026-11-30. Check the company's investor-relations page.
- Is RDNT a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology